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Abstract: Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin
(mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an
attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting
H-ferritin nanocages (HEve) to improve its subcellular delivery. We took advantage of the natural
tumor targeting of H-Ferritin, which is mediated by the transferrin receptor-1 (TfR1). Breast cancer
cells overexpressing TfR-1 were successfully recognized by H-Ferritin, displaying quick nanocage
internalization. HEve has been tested and compared to Eve for in vitro efficacy in sensitive and resistant
breast cancer cells. Nanoformulated Eve induced remarkable antiproliferative activity in vitro, making
even resistant cell lines sensitive to Eve. Moreover, the antiproliferative activity of HEve is fully in
accordance with cytotoxicity observed by cell death assay. Furthermore, the significant increase in
anticancer efficacy displayed in HEve-treated samples is due to the improved drug accumulation,
as demonstrated by UHPLC-MS/MS quantifications. Our findings suggest that optimizing Eve
subcellular delivery, thanks to nanoformulation, determines its improved antitumor activity in a
panel of Eve-sensitive or resistant breast cancer cell lines.
Keywords: breast cancer; Everolimus; nanoparticles; H-ferritin
1. Introduction
Advanced breast cancer (BC) still represents a clinical challenge due to the high rate of
chemoresistance and consequent cancer progression, both in hormone receptor-positive and negative
subtypes [1]. Different drivers of resistance have been described for HER2-positive, triple-negative,
and hormone receptor-positive cancers. Intriguingly, a common shared feature has been identified
downstream in the proliferative pathway of BC cells: the hyperactivation of the phosphatidylinositol
3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway irrespectively from the
growth factor receptors status [2]. The PI3K/AKT/mTOR pathway can display different pathological
alterations, such as the downregulation of the tumor suppressor PTEN [3–5], the abnormal activation
of PI3K [6–8], or the overexpression/hyperactivation of AKT [9]. Everolimus (Eve; RAD001, Afinitor®)
is an FDA-approved rapamycin analog that acts inside the cytoplasmatic compartment, inhibiting the
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PI3K/AKT/mTOR pathway. Specifically, Eve inhibits mTOR, interrupting its signaling cascade and
resulting in inhibition of cell proliferation and growth [10]. Although Eve is currently approved for
second-line treatment of metastatic BC, sometimes showing encouraging results, conflicting clinical data
have been reported on its efficacy, particularly in some hormone receptor-positive and in triple-negative
BC. Furthermore, a relatively small advantage in progression-free survival is severely paid by patients
with the well-known Eve-related toxicities, mainly stomatitis, affecting the quality of life [1,2].
Nanotechnology has offered new opportunities to overcome current major challenges of
chemotherapy through biological targeted nanosystems [11,12]. In particular, H-ferritin (HFn)
nanocages hold a great promise thanks to their specific tumor homing mediated by Transferrin
Receptor-1 (TfR1) internalization [13,14]. HFn is a 12 nm cave sphere constituted by 24 H-subunits of
ferritin protein. H-monomers have been produced in E. coli by DNA recombinant technology and
they self-assemble into their spherical quaternary structure after protein synthesis. Moreover, from
the nanotechnological point of view, they combine low toxicity with high stability in biological fluids
and with the possibility to load different kind of molecules inside its cavity [14–19]. Therefore, several
HFn-based nanodrugs have been developed, obtaining specific tumor recognition, improved drug
penetration, and increased activity with reduced side-effects due to toxicity. Furthermore, it has been
demonstrated that nanoformulation in HFn has a role in avoiding the onset of chemoresistance [20].
Despite this, the potential of HFn as nanovector to deliver drug inside the cytoplasm has not been well
investigated and only indirect data could be found [19].
Here, we exploited the development of an HFn-based nanoformulation of Everolimus (HEve) for
the treatment of different subtypes of BC, regardless of their PI3K/AKT/mTOR activity status.
The aim of the present study was to assess HEve anticancer efficacy in comparison with free Eve
in Eve-sensitive (i.e., BT474) and Eve-resistant (i.e., SKBR3, MDA-MB 231 and MCF-7) cell lines.
2. Materials and Methods
2.1. H-Ferritin (HFn)
HFn were purchased from Molirom s.r.l. (Rome, Italy). HFn was labelled with fluoresceine
isothiocyanate Isomer I (Sigma-Aldrich S.r.l., CAS Number: 3326-32-7, Milan, Italy) according to the
manufacturer’s protocol (Sigma-Aldrich S.r.l, Milan, Italy) for interaction studies with BC cell lines.
2.2. HFn Loading with Eve
HEve was prepared using the drug complexation with Cu(II) [15]. Everolimus powder (25 mg;
Aurogene S.r.l., Rome, Italy; S1120-25MG) was previously solubilized in Ethanol (2.5 mL; 10 mg/mL).
Eve (100 µg) was incubated for 10 min at RT with 10 mM CuSO4 obtaining a Cu(II)–Eve complex.
The complexed drug was added to HFn (1 mg) and then incubated for 2 h at RT. HEve was separated
from free Eve by a gel filtration to Zeba™ Spin Desalting Column (Thermo Fisher Scientific, Monza,
Italy; Catalog Number: 89890). Protein content of HFn in HEve sample was assessed by Bradford assay
(Thermo Fisher Scientific, Monza, Italy; Catalog Number: 23200), while the quantitative UPLC/MS-MS
analysis determined the amount of encapsulated Eve.
2.3. Eve Quantification
Eve quantification was performed by an Ultra High Performance Liquid Chromatography
(UHPLC) system equipped with a Triple Quadrupole Mass Spectrometer (6460 Agilent Technologies,
Santa Clara, CA, USA). The instrument, operating in positive mode with electrospray ionization
interface (ESI), was used to carry out MS/MS analysis (UHPLC-MS/MS). For the chromatographic
conditions, a Zorbax Eclipse plus C18 2.1 × 50 mm 1.8 µm column was used. The chromatographic run
time was 6 min.
To quantify HEve after the loading procedure, 80 µL of cold acetonitrile was added to 20 µL
of HEve sample. Then, the mixture was vortexed and centrifuged (10 min, 14,000 rpm) in order to
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precipitate HFn. Fifty microliters of the supernatant was diluted with mobile phase. Afterwards,
100 µL of the sample with its internal standard (EveD4) was directly injected into the UHPLC-MS/MS
system. A six-point calibration curve (62.5–2500 ng/mL) was used to quantify Eve encapsulated in HFn.
In order to obtain the precipitation solution, a mineral acid (37% HCl) was diluted in acetone.
PBS samples were vortexed and incubated in an ice bath for 30 min and then centrifuged for 15 min
at 14,000 rpm. Afterwards, the supernatant was dried under a weak flow of nitrogen (N2). Samples
were then reconstituted in 100 µL of mobile phase prior to UHPLC-MS/MS analysis. To quantify drug
release, the calibration curve was prepared in PBS and ranged between 5.0 and 50.0 ng/mL.
For HEve quantification in cytoplasm, a solid phase extraction (SPE) procedure followed the protein
precipitation. The residue was reconstituted with aqueous phase and loaded onto preconditioned
cartridges. Then, 100 µL of mobile phase was used to inject the samples into the UHPLC-MS/MS
system. The limit of detection (LOD) of the analytical method was set at 0.5 ng/mL. The calibration
curve prepared in the matrix used throughout the study was linear between 1.0 and 50.0 ng/mL sample.
2.4. Transmission Electron Microscopy
A drop of HFn suspension was positioned on the Formvar net and dried at RT. Then, the net was
stained with uranil-acetate 1% for 30 s at RT and dried over night at RT [15]. Samples were evaluated
by Transmission Electron Microscopy (Tecnai Spirit, FEI, Hillsboro, OR, USA). Magnification 220,000×
and 135,000×.
2.5. Kinetics of Spontaneous Eve Release In Vitro
HEve was collected in a dialysis device (Float-A-lyzer G2 Dialysis Device MWCO: 100 KD,
SpectrumLABS, Compton, CA, USA) and kept in a PBS bath at 37 ◦C for seven days. At predetermined
time points (15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5h, 6 h, 24 h, 48 h, 72 h, 96 h, 168 h), 5 mL of buffer were
collected and replaced with fresh buffer in order to maintain sink condition. The amount of released
drug in each collected sample was quantified by UPLC/MS-MS, as described above.
2.6. Cell Cultures
SKBR3, MCF-7, and MDA-MB-231 cell lines were purchased by ATCC-LGC Standards and Caliper
LifeSciences, respectively. BT474 was kindly provided by Dr. Libero Santarpia (IRCCS Humanitas
Clinical and Research Center, Milano, Italy).
BT474 and MCF-7 cells were cultured in DMEM Medium supplemented with 10% FBS, l-glutamine
(2 mM), penicillin (50 UI/mL) and streptomycin (50 mg/mL). SKBR3 were cultured in DMEM/Ham’s
F12 Medium supplemented with 10% FBS, l-glutamine (2 mM), penicillin (50 UI/mL) and streptomycin
(50 mg/mL). MDA-MB 231 cells were cultured in MEM Medium supplemented with 10% FBS,
l-glutamine (2 mM), penicillin (50 UI/mL), and streptomycin (50 mg/mL). All cell lines grow at
37 ◦C in humidified atmosphere containing 5% CO2 and were subcultured prior to confluence using
trypsin/EDTA. Cell culture medium and chemicals for cell culture were purchased from Euroclone
S.p.A.
2.7. TfR1 Expression
SKBR3, BT474, and MCF-7 cells (5 × 105) were labelled in FACS tubes with anti-TfR1 antibody
diluted 1:100 (1 µg/tube; CD71 Antibody (clone ICO-92), Thermo Fisher Scientific, Catalog Number #:
MA1-7657) in blocking buffer (PBS, 2% Bovine Serum Albumin (BSA; Sigma-Aldrich S.r.l., Milan, Italy)
and 2% goat serum (Euroclone S.p.A., Pero, Italy) for 30 min at RT and cells were washed three times
with PBS. Then, cells were labelled with Alexa Fluor 488 goat anti-mouse secondary antibody diluted
1:200 (1 µL/tube; Thermo Fisher Scientific, Monza, Italy; Catalog Number #: A-11001) in blocking buffer
for 30 min at RT and were washed thrice with PBS before analysis using CytoFLEX flow cytometer
(Beckman Coulter, Cassina De’ Pecchi, Italy). 20,000 events were acquired, after gating on viable cells
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and on singlets. Cells immunodecorated with secondary antibody only were used to set the region
of positivity.
2.8. In Plate-Cell Binding Assay at 37 ◦C
A total of 5 × 105 cells was seeded on a six -well plate. The day after seeding, cells were incubated
for 1 h at 37 ◦C in culture medium with 10 and 100 µg/mL of FITC-labelled HFn. After incubation, cells
were washed thrice with PBS, collected from the plate with trypsin/EDTA and suspended in 0.5 mL
of PBS before analysis using CytoFLEX flow cytometer (Beckman Coulter, Cassina De’ Pecchi, Italy).
A total of 20,000 events was analyzed for each sample, after gating on viable cells and on singlets.
The appropriate gates were set using a sample of untreated cells.
2.9. HFn Internalization—Confocal Laser Scanning Microscopy
A total of 2 × 105 cells was seeded on cover glass slides precoated with collagen in a six-well
plate. The day after seeding, cells were treated with 100 µg/mL of FITC-labelled HFn for different time
periods (15 min, 1, 3 and 24 h) at 37 ◦C to evaluate the intracellular fate of HFn. After incubations,
cells were washed with PBS, fixed 5 min with 4% paraformaldehyde (Sigma-Aldrich S.r.l., Milan, Italy)
and then permeabilized 5 min with 0.1% Triton X-100 (Sigma-Aldrich S.r.l., Milan, Italy). A blocking
step was executed for 1 h at RT with a solution containing 2% BSA (Sigma-Aldrich S.r.l., Milan, Italy),
2% goat serum (Euroclone S.p.A., Pero, Italy) and 0.2 µg/mL DAPI (4′,6-diamino-2-phenylindole;
Thermo Fisher Scientific, Monza, Italy). Confocal microscopy images were acquired with the Leica SP8
system equipped with laser excitation lines at 405, 488, 552, and 633 nm, using 63×magnification oil
immersion lenses at 1024 × 1024 or 512 × 512 pixel resolution.
2.10. Cell Viability Assay
Cells were seeded on a 96-well well plate at the density of 4,000 cells cm−1 and the day after were
incubated with different amounts of Eve or HEve (1, 10, 50 and 100 nM). After 72 h of treatment, cells
were washed with PBS before incubation for 3 h at 37 ◦C with 0.1 mL of a stock solution of 3-(4,5-dim
ethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine
ethosulfate (PES) previously diluted five times in phenol red-free medium (CellTiter 96® AQueous
One Solution Reagent; Promega, Madison, WI, USA; Catalog #: G5421). A microplate reader (BioTek,
Milan, Italy) read absorbance using a testing wavelength of 490 nm and a reference wavelength of
620 nm. Untreated samples were used to normalize the results and expressed as means ± s.e.
2.11. Cell Death Assay
A total of 2 × 105 cells was seeded on a 12-well plate and treated for 72 h in the presence of
different amounts of Eve or HEve (10, 50, and 100 nM). Untreated cells represented negative control.
At the end of incubation, cells were collected and washed three times with PBS. Then, cells were
suspended in Binding Buffer and incubated for 5 min with 5 µL of Annexin V-PE-Cy5, according to
Annexin V-PE-Cy5 Apoptosis Detection Kit manufacturer’s protocol (BioVision, Milpitas, CA, USA;
Catalog #: K129-100). CytoFLEX flow cytometer (Beckman Coulter, Cassina De’ Pecchi, Italy) was
used to acquire 20,000 events/sample.
2.12. Quantification of Cytoplasmatic Accumulation of Eve
A total of 1 × 106 cells was seeded on a six-well plate and incubated at 37 ◦C with Eve or HEve
(10, 50 and 100 nM) for 24 h. At the end of incubation time, cells were collected with Trypsin/EDTA
and centrifuged 5 min at 2000 rpm. Pellets were washed two times with PBS, suspended in 1 mL of
Nuclei Extraction Buffer (10 mM Hepes, pH 7.4, 320 mM Sucrose, 5 mM MgCl, 1% Triton X-100) before
incubation on ice for 10 min. Cytoplasm was separated by nuclei centrifuging the sample 5 min at
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2000 rpm. The supernatant (cytoplasmatic fraction) was collected and processed for UPLC/MS-MS
evaluation of Eve content.
3. Results
3.1. HFn Nanoparticles: Interaction with Tumor Cells and Internalization
In order to develop a nanodrug delivery system able to improve Eve penetration in BC cells,
we have previously assessed the capability of HFn to target the MDA-MB 231 TNBC cell line [15]. Here,
we demonstrated its targeting efficiency also in BT474, SKBR3, and MCF-7. This allowed us to evaluate
the capability of HFn nanocages to interact with a panel of in vitro models of BC, using cell lines
both sensitive (BT474) and resistant (SKBR3, MDA-MB 231, MCF-7) to Eve, according to classification
reported by Hurvitz et al. [21]. Moreover, all the major BC subtypes have been represented since
HER2-positive (i.e., BT474 and SKBR3), triple-negative (i.e., MDA-MB 231), and estrogen receptor
positive (i.e., MCF-7) cell lines have been employed. All these cells display a good degree of Transferrin
Receptor-1 (TfR1) expression, suggesting the positive role of HFn nanocages in improving drug
internalization (Supplementary Figure S1) [15]. To assess the suitability of HFn as targeted delivery
system for Eve, we have evaluated its interaction with the selected panel of BC cells performing a
binding assay in physiological conditions (37 ◦C, 5% CO2).
BT474, SKBR3, and MCF-7 cells have been incubated 1 h with increasing concentrations of
fluoresceine isothiocyanate (FITC)-labelled HFn (10 or 100 µg/mL). Then, the binding percentage has
been assessed by flow cytometry, demonstrating a good and dose-dependent capability of HFn to
recognize all the tested cell lines (Figure 1, Supplementary Figures S2–S4), confirming the interaction’s
data already published with MDA-MB 231 [15]. Moreover, the binding percentage at 10 µg/mL
was assessed.
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Figure 1. HFn recognition of BC cells. BT474, SKBR3, and CF-7 cells were incubated for 1 h at 37 ◦C
in co plete cell culture ediu ith different a ounts of FITC-labelled Fn nanoparticles (10 and
100 µg/ L). Then, cells were collected, washed, and processed for flow cytometry, using untreated cells
to set the positive and the singlet gates. Reported values are the means ± s.e. (n = 3).
HF is indirectly related to TfR1 expression, a expected when specific binding takes place. Indeed,
in SKBR3 cells hat display low TfR1 expression, there are few HFn binding sites per cell, so less HFn i
necessary to saturate them, as d monst ated by SKBR3 results at 10 µg/mL (Supplementary Figure S4).
Otherwise, in cells lines with higher TfR1 expression (i.e., BT474 a d MCF-7), binding ite saturati n
occurs at higher HFn dosages (Supplementary igures S2 and S3).
Confocal laser scanning images of BC cells incubated with FITC-labell d HFn nanoparticles
evidence that a fast interaction with cellu ar membrane occurred, since FITC-labelled HFn was
attached to the cell surface even after 15 min of incubation. In addition, FITC-labelled HFn was already
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internalized after 1 h of incubation and, after 3 h, the internalization process was almost complete.
After 24 h, the fluorescence signal of FITC-labelled HFn decreased (Figure 2), in accordance with results
from previous studies [17,20], suggesting that HFn nanocages were degraded or combined with native
HFn, which is unlabelled.Pharmaceutics 2019, 11, x 6 of 14 
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Next, Eve release from HFn was analyzed in physiological conditions to assess the kinetic of release
from HFn nanocage. This kinetic was estimated by dialyzing HEve at 37 ◦C in phosphate-buffered saline
(PBS) and measuring Eve leakage from HFn by UHPLC-MS/MS quantification in the supernatants.
Eve is released following first order kinetics with a constant release of drug (6–7% every hour) during
the first 6 h. After 24 h, the kinetic slows down to 6–7% of release/day (Figure 4).
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3.3. HEve Exhibits Enhanced Anticancer Activity in Tumor Cells
To further investigate the quality of the HEve nanodrug, we have assessed its antitumor efficacy
in comparison with Eve in a panel of TNBC, HER2, and ER positive cell lines. Cells have been treated
with different amounts of Eve or HEve in a concentration range between 1 and 100 nM for 72 h
(Figure 5) and the percentage of viable cells was assessed by MTS assay, normalizing treated samples
toward untreated controls. BT474 cell viability was affected by treatment with 10, 50, and 100 nM Eve
and HEve (Figure 5) in a similar manner. However, the Eve nanoformulation in HFn significantly
increased the anticancer effect of Eve at 1 nM concentration, as evidenced in Figure 5, suggesting the
potential role of nanoformulation in reducing drug-dosage in Eve-sensitive tumor cells. Furthermore,
the nanoformulation in HFn displayed a positive contribution in Eve-resistant cell lines. Indeed, HEve
exhibited an increase in antitumor activity as compared to Eve in SKBR3 cells (Figure 5), revealing a
significant difference in the anticancer potential between the free and nanoformulated drug. Moreover,
HEve was able to cause a notable reduction in MDA-MB 231 and MCF-7 cell viability, while free Eve
did not affect viability of these cell lines (Figure 5). Although several evidences about the overall safety
of the HFn nanocages have been already available in literature [15], we have assessed the effect of void
HFn nanocages on BT474, SKBR3, and MCF-7 cells. MTS assay results reported in Supplementary
Figure S5 confirmed that HFn does not affect BC cells’ viability. To exclude a toxic contribution of
copper used for the encapsulation reaction, we performed MTS assays incubating cells with 1.5, 0.15,
and 0.015 µM of copper. Results reported in supplementary Figure 6 clearly evidence that cell viability
is not affected by copper in assay conditions. On the whole, viability results clearly evidenced the
positive contribution of HFn nanoformulation in increasing the therapeutic potential of Eve both in
sensitive and resistant cell lines.
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3.4. The Treatment with HEve Determines Cell Apoptosis
Next, in order to determine if the reduced proliferation observed in HEve treated samples was
associated with an increase in cell death, we have assessed the exposure to Annexin V, which is
expected to only occur in apoptotic cells. BC cells were incubated for 72 h with Eve or HEve at different
concentrations, including 10 nM, 50 nM, and 100 nM. Annexin V exposure was measured by flow
cytometry using untreated cells to set the regions of positivity. The percentage of dead cells reported
in Figure 6 demonstrated that HEve was much more effective than free Eve in inducing apoptosis at
low concentrations in the sensitive cell line (i.e., BT474). At higher concentrations of Eve, differences
between free or nanoformulated drug were smoothed, as expected, since we hypothesized that the
positive contribution of nanoformulation is mainly due to a more efficient and rapid delivery of drug
inside the cells.
Eve-resistant SKBR3 and MDA-MB 231 cells treated with low concentration of HEve did not
show any significant increase in cell death in comparison with free drug, since the Eve dosage was
probably too low to significantly affect cell death (Figure 6 and Figure S7). However, increasing drug
concentrations up to 100 nM made the advantage of nanoformulated HEve in comparison to free Eve
clear (Figure 6 and Figure S7). Instead, in the MCF-7 cell line (Figure 6), Eve-induced apoptosis is visible
in test conditions. Therefore, the ability of nanoformulated Eve to induce cell death is prominent.
3.5. HFn Mediates Cytoplasmatic Delivery of Eve
To explain the increased efficacy of Eve upon HFn nanoformulation, we have hypothesized a
positive role of HFn in mediating drug uptake, thus increasing the amount of payload released into the
cytoplasmatic compartment. Therefore, we incubated BT474 cells for 24 h and 72 h with 10 or 100 nM
Eve or HEve and measured the amount of drug accumulated in the cytoplasmatic compartment by
UHPLC-MS/MS, in order to investigate whether HFn could play an active role in the cytoplasmatic
delivery of Eve. Results reported in Table 2 show that HFn played a crucial role in improving Eve
cytoplasmatic accumulation (Table 2). Indeed, in cells treated with free Eve, the amount of drug is
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below the detection limit, while in samples treated with 100 nM HEve, the drug is clearly detected in
the cytoplasm.
Table 2. Cytoplasmic extract. Reported values are the mean of three samples ± s.e. Statistical
significance of HEve vs. free drug. * p < 0.05; ** p < 0.0005 (Student’s t-test).
Sample Conc (ng/mL) Time (hours)
Eve 1 0 nM <0.5 24
Eve 100 nM <0.5 24
HEve 10 nM <0.5 24
* HEve 100 nM 1.94 ± 0.36 24
Eve 10 nM <0.5 72
Eve 100 nM <0.5 72
HEve 10 nM <0.5 72
** HEve 100 nM 3.74 ± 0.08 72
4. Discussion
Eve’s FDA approval is limited to the treatment of hormone receptor-positive advanced BC in
progression after aromatase inhibitor treatment, if associated to exemestane, following the findings from
the BOLERO-2 trial [1]. However, controversial results have been reported with triple-negative BC in the
adjuvant setting and, in one report, also in the neoadjuvant setting [2]. Also, in HER2-positive disease,
adding Eve after occurrence of resistance to trastuzumab has demonstrated a relatively limited benefit,
according to findings of the BOLERO-3 trial [23]. However, dysregulation of the PI3K/AKT/mTOR
pathway is widely reported among BC cell subtypes, suggesting that there may be a window of
opportunity for administration of Eve in BC, independent of the biological subtype [24]. Furthermore,
the limited benefit of Eve, particularly in hormone receptor-negative BC, is counterbalanced by a high
toxicity due to off-target actions of the drug, particularly grade 3–4 neutropenia and stomatitis [1,2].
Here, a novel nanodrug consisting of H-ferritin nanoparticles loaded with Eve was developed, tested,
and compared to free Eve for in vitro efficacy on sensitive and resistant BC cell lines used as in vitro
models of HER2+, triple-negative, and ER+ BC. Our study’s goal was to increase the spectrum of
action of Eve by optimizing its cellular uptake and subcellular delivery by nanoformulation in HFn
nanocages. HFn displays natural tumor homing thanks to its capability to specifically recognize cancer
cells by exploiting the interaction with TfR1 [13,15,20,25]. This receptor is overexpressed in cancer cells
as a result of their active iron metabolism [13].
Although the amount of Eve encapsulated in HFn nanocages is lower than observed with other
drugs [13,20], its formulation in HFn nanocages increases the drug’s ability to inhibit BC cell proliferation
thanks to its increased cellular uptake, probably due to TfR1-mediated internalization [13]. TfR1 is
a key factor in iron homeostasis, together with transferrin. In healthy tissues, TfR1 is ubiquitously
expressed at low levels, while in tumors it is overexpressed due to the highly active iron metabolism
that characterizes this pathology. [25,26]. TfR1 is also able to bind and internalize circulating Ferritin
by exploiting a specific interaction with the H-ferritin chain [25]. Therefore, the development of
nanoformulated anticancer drugs using nanocages of H-ferritin is a reasonably good solution to
improve drug effectiveness [14,15,19,20]. As confirmed by flow cytometry, all BC cell lines used here
display TfR1 overexpression (Figure S1); therefore, there is good binding between HFn nanocages and
cells (Figure 1). The HFn binding of BC cells drives rapid nanocage internalization, as evidenced in
Figure 2.
Nanoformulation confers Eve with remarkable antiproliferative activity as compared to free
Eve in all tested lines, making resistant cell lines sensitive to Eve (Figure 5). HEve showed a higher
antiproliferative effect at 1 nM concentration and significantly improved cell death compared to free
Eve. Similarly, by using HEve it is possible to reduce drug dosages, as evidenced in Figure 5 with BT474
cells, where the same antiproliferative effect could be obtained with 1 nM HEve or with 100 nM Eve.
Antiproliferative results of HEve are full in accordance with cytotoxic activity observed by cell death
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assay. Here, HEve is more effective than Eve in inducing cell death in Eve-resistant cells (Figure 6 and
Figure S7), confirming a role of nanoformulation in powering the antitumor activity of Eve. Although
the 10–15% decrease in viability observed in luminal MCF-7 cells was expected, its coupling with a
high induction of cell death needs to be better explained. The increased PI3K activity, resulting from
a high PI3KCA gene copy number and activating PI3KCA point mutations found in MCF-7 cells,
determines hyperactivation of AKT [24], which stimulates cell proliferation in different ways [27].
Here, the inhibition of mTOR-dependent proliferation due to Eve treatment is negligible in comparison
to the stimulated proliferation induced by other AKT effectors and therefore explains the limited but
significant reduction in viability observed upon Eve and HEve treatment [27]. However, the more
pronounced effects observed in the cell death assay find an explanation in the molecular profile of
this cell line. MCF-7 does not express caspase-3; it exploits alternative apoptotic mechanisms [28] that
generally result in quicker cell death in comparison to caspase-3-expressing cells [29].
Triple-negative BC cell lines less frequently rely on the PI3K/AKT/mTOR pathway [24]. The findings
of our study suggest that low doses of nanoformulated Eve allow the drug to be internalized at higher
concentrations in the cytoplasm, thus exerting a relevant effect in cell lines such as MDA-MB 231.
Furthermore, the results of the cell death assay performed on Eve-sensitive cell lines support HFn
nanoformulation in order to reduce drug dosage.
Since all the tested BC cell lines display a significant increase in anticancer efficacy by HEve,
UHPLC-MS/MS results demonstrate that it is due to the improved drug uptake following HFn
nanoformulation. However, different responses to HEve could occur in other BC cell lines, since Eve
uptake could be differently influenced by TfR1 expression. In addition, Eve sensitivity is a parameter
to take into account. Further studies are needed to exactly disclose the incidence of these two features.
However, our results support the therapeutic success of HEve in a relevant panel of BCs and the quick
HFn uptake observed by confocal microscopy in all BC cell lines (Figure 2) suggests that the advantage
due to delivery could be similarly effective in cells with different TfR1 expression levels.
Finally, few instances of Everolimus-loaded nanoparticles have been developed in the literature.
These include gold nanoparticles decorated with CD44 and chitosan nanoparticles decorated with
hyaluronic acid and CD44 [30–32]. However, these applications are related to other pathologies.
Moreover, in the case of gold nanoparticles, an increase in drug efficacy upon nanoformulation was
not documented. Only one work employed PLGA nanoparticles loaded with Eve to treat cancer, but in
this case, efficacy was only achieved through codelivery with paclitaxel [33].
5. Conclusions
Here, a novel H-ferritin-based Eve nanoformulation has been developed, tested, and compared to
free Eve on sensitive and resistant HER2+, triple-negative, and ER+ BC cell lines. By optimizing Eve’s
subcellular delivery, we have improved its antitumor activity.
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